Regeneron Pharmaceuticals Inc. buy BMO Capital Markets
Summary
This prediction is currently active. The prediction currently has a performance of 24.94%. This prediction currently runs until 05.02.25. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 0.000% | 0.000% |
iShares Core DAX® | 1.560% | 2.566% |
iShares Nasdaq 100 | 0.517% | 1.894% |
iShares Nikkei 225® | 1.730% | 5.631% |
iShares S&P 500 | 1.482% | 1.594% |
Comments by BMO_Capital_Markets for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren